New Zealand Approves MDMA Prescription for Severe PTSD Treatment
Quick Brief
New Zealand health authorities have granted approval for two psychiatrists to prescribe pharmaceutical-grade MDMA. The substance will be used to treat patients suffering from severe post-traumatic stress disorder. This decision marks a significant shift in the medical application of the psychoactive compound.
What Happened?
Two psychiatrists in New Zealand received official approval on Friday to begin prescribing pharmaceutical-grade MDMA to individuals experiencing severe post-traumatic stress disorder (PTSD).
Why It Matters
The authorization represents a major development in the medical acceptance and therapeutic use of MDMA, traditionally known as a party drug, for addressing severe mental health conditions like PTSD.
Key Facts
- Two psychiatrists in New Zealand gained approval to prescribe MDMA.
- The authorization was granted on Friday.
- The approved substance is pharmaceutical-grade MDMA.
- Treatment is targeted at sufferers of severe post-traumatic stress disorder (PTSD).
Compiled from 1 outlet
Related Stories
Gene-Edited Pig Kidney Transplants Reach Major Milestone as Patients Progress to Human Organs
Patients who received groundbreaking gene-edited pig kidney transplants have successfully operated with the animal organs for extended periods. One patient lived with the world's first pig kidney transplant for nine months, lasting 271 days, before ultimately progressing to a human kidney transplant.
Growing Scrutiny and Social Stigma Surround Mass-Prescribed GLP-1 Medications
The widespread prescription of GLP-1 medications has triggered growing public scrutiny and social debate. Experts are increasingly calling for safer weight loss practices as patients report facing intense social shaming and pressure regarding their use or non-use of the drugs.
New Zealand Approves MDMA Treatment for Severe PTSD
New Zealand's drug regulatory body, Medsafe, has granted approval for two psychiatrists to prescribe pharmaceutical-grade MDMA for severe post-traumatic stress disorder. This decision makes New Zealand the second country globally to approve the psychedelic substance for therapeutic use, following Australia's similar authorization in 2023.
Scientific Study Reveals Inaccuracies in Smartwatch Calorie Tracking
Recent scientific research highlights significant inaccuracies in how smartwatches measure calorie burn during physical activity. Evaluating four major brands, studies indicate that users cannot fully trust these health metrics, with Garmin showing the least accurate performance.